Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

Akira Okada, Misato Kariya, Kei Irie, Yutaka Okada, Nobuhiro Hiramoto, Hisako Hashimoto, Ryosuke Kajioka, Chika Maruyama, Hidefumi Kasai, Mami Hamori, Asako Nishimura, Nobuhito Shibata, Keizo Fukushima, Nobuyuki Sugioka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Vancomycin is a commonly used antimicrobial agent for patients undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Vancomycin has large inter- and intraindividual pharmacokinetic variability, which is mainly described by renal function; various studies have indicated that vancomycin pharmacokinetics are altered in special populations. However, little is known regarding vancomycin pharmacokinetics in patients undergoing allo-HSCT. Therefore, we aimed to develop a population pharmacokinetic (PopPK) model of vancomycin in patients undergoing allo-HSCT for effective and safe antimicrobial therapy and to develop a vancomycin dosing nomogram for a vancomycin optimal-dosing strategy. In total, 285 observations from 95 patients undergoing allo-HSCT were available. The final PopPK parameter estimates were central volume of distribution (V1, L), 39.2; clearance (L/h), 4.25; peripheral volume of distribution (V2, L), 56.1; and intercompartmental clearance (L/h), 1.95. The developed vancomycin model revealed an increase in V1 and V2 compared with those in the general population that consisted of patients with methicillin-resistant Staphylococcus aureus. Moreover, serum creatinine was reduced because of an increase in the plasma fraction because of destruction of hematopoietic stem cells accompanying allo-HSCT pretreatment, suggesting that the Cockcroft–Gault equation–based creatinine clearance value was overestimated. To our knowledge, this is the first PopPK study to develop a dosing nomogram for vancomycin in patients undergoing allo-HSCT and was proven to be useful in optimizing the dosage and dosing interval of vancomycin in these patients. This strategy will provide more useful information for vancomycin therapy with an evidence-based dose adjustment.

Original languageEnglish
Pages (from-to)1140-1149
Number of pages10
JournalJournal of Clinical Pharmacology
Volume58
Issue number9
DOIs
Publication statusPublished - 2018 Sep
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Vancomycin
Pharmacokinetics
Population
Nomograms
Creatinine
Methicillin-Resistant Staphylococcus aureus
Hematopoietic Stem Cells
Anti-Infective Agents
Kidney

Keywords

  • allogeneic hematopoietic stem-cell transplantation
  • population pharmacokinetics
  • renal function
  • vancomycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation. / Okada, Akira; Kariya, Misato; Irie, Kei; Okada, Yutaka; Hiramoto, Nobuhiro; Hashimoto, Hisako; Kajioka, Ryosuke; Maruyama, Chika; Kasai, Hidefumi; Hamori, Mami; Nishimura, Asako; Shibata, Nobuhito; Fukushima, Keizo; Sugioka, Nobuyuki.

In: Journal of Clinical Pharmacology, Vol. 58, No. 9, 09.2018, p. 1140-1149.

Research output: Contribution to journalArticle

Okada, A, Kariya, M, Irie, K, Okada, Y, Hiramoto, N, Hashimoto, H, Kajioka, R, Maruyama, C, Kasai, H, Hamori, M, Nishimura, A, Shibata, N, Fukushima, K & Sugioka, N 2018, 'Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation', Journal of Clinical Pharmacology, vol. 58, no. 9, pp. 1140-1149. https://doi.org/10.1002/jcph.1106
Okada, Akira ; Kariya, Misato ; Irie, Kei ; Okada, Yutaka ; Hiramoto, Nobuhiro ; Hashimoto, Hisako ; Kajioka, Ryosuke ; Maruyama, Chika ; Kasai, Hidefumi ; Hamori, Mami ; Nishimura, Asako ; Shibata, Nobuhito ; Fukushima, Keizo ; Sugioka, Nobuyuki. / Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation. In: Journal of Clinical Pharmacology. 2018 ; Vol. 58, No. 9. pp. 1140-1149.
@article{38a1766a4c35462899bcde8ca0c94cd7,
title = "Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation",
abstract = "Vancomycin is a commonly used antimicrobial agent for patients undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Vancomycin has large inter- and intraindividual pharmacokinetic variability, which is mainly described by renal function; various studies have indicated that vancomycin pharmacokinetics are altered in special populations. However, little is known regarding vancomycin pharmacokinetics in patients undergoing allo-HSCT. Therefore, we aimed to develop a population pharmacokinetic (PopPK) model of vancomycin in patients undergoing allo-HSCT for effective and safe antimicrobial therapy and to develop a vancomycin dosing nomogram for a vancomycin optimal-dosing strategy. In total, 285 observations from 95 patients undergoing allo-HSCT were available. The final PopPK parameter estimates were central volume of distribution (V1, L), 39.2; clearance (L/h), 4.25; peripheral volume of distribution (V2, L), 56.1; and intercompartmental clearance (L/h), 1.95. The developed vancomycin model revealed an increase in V1 and V2 compared with those in the general population that consisted of patients with methicillin-resistant Staphylococcus aureus. Moreover, serum creatinine was reduced because of an increase in the plasma fraction because of destruction of hematopoietic stem cells accompanying allo-HSCT pretreatment, suggesting that the Cockcroft–Gault equation–based creatinine clearance value was overestimated. To our knowledge, this is the first PopPK study to develop a dosing nomogram for vancomycin in patients undergoing allo-HSCT and was proven to be useful in optimizing the dosage and dosing interval of vancomycin in these patients. This strategy will provide more useful information for vancomycin therapy with an evidence-based dose adjustment.",
keywords = "allogeneic hematopoietic stem-cell transplantation, population pharmacokinetics, renal function, vancomycin",
author = "Akira Okada and Misato Kariya and Kei Irie and Yutaka Okada and Nobuhiro Hiramoto and Hisako Hashimoto and Ryosuke Kajioka and Chika Maruyama and Hidefumi Kasai and Mami Hamori and Asako Nishimura and Nobuhito Shibata and Keizo Fukushima and Nobuyuki Sugioka",
year = "2018",
month = "9",
doi = "10.1002/jcph.1106",
language = "English",
volume = "58",
pages = "1140--1149",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

AU - Okada, Akira

AU - Kariya, Misato

AU - Irie, Kei

AU - Okada, Yutaka

AU - Hiramoto, Nobuhiro

AU - Hashimoto, Hisako

AU - Kajioka, Ryosuke

AU - Maruyama, Chika

AU - Kasai, Hidefumi

AU - Hamori, Mami

AU - Nishimura, Asako

AU - Shibata, Nobuhito

AU - Fukushima, Keizo

AU - Sugioka, Nobuyuki

PY - 2018/9

Y1 - 2018/9

N2 - Vancomycin is a commonly used antimicrobial agent for patients undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Vancomycin has large inter- and intraindividual pharmacokinetic variability, which is mainly described by renal function; various studies have indicated that vancomycin pharmacokinetics are altered in special populations. However, little is known regarding vancomycin pharmacokinetics in patients undergoing allo-HSCT. Therefore, we aimed to develop a population pharmacokinetic (PopPK) model of vancomycin in patients undergoing allo-HSCT for effective and safe antimicrobial therapy and to develop a vancomycin dosing nomogram for a vancomycin optimal-dosing strategy. In total, 285 observations from 95 patients undergoing allo-HSCT were available. The final PopPK parameter estimates were central volume of distribution (V1, L), 39.2; clearance (L/h), 4.25; peripheral volume of distribution (V2, L), 56.1; and intercompartmental clearance (L/h), 1.95. The developed vancomycin model revealed an increase in V1 and V2 compared with those in the general population that consisted of patients with methicillin-resistant Staphylococcus aureus. Moreover, serum creatinine was reduced because of an increase in the plasma fraction because of destruction of hematopoietic stem cells accompanying allo-HSCT pretreatment, suggesting that the Cockcroft–Gault equation–based creatinine clearance value was overestimated. To our knowledge, this is the first PopPK study to develop a dosing nomogram for vancomycin in patients undergoing allo-HSCT and was proven to be useful in optimizing the dosage and dosing interval of vancomycin in these patients. This strategy will provide more useful information for vancomycin therapy with an evidence-based dose adjustment.

AB - Vancomycin is a commonly used antimicrobial agent for patients undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Vancomycin has large inter- and intraindividual pharmacokinetic variability, which is mainly described by renal function; various studies have indicated that vancomycin pharmacokinetics are altered in special populations. However, little is known regarding vancomycin pharmacokinetics in patients undergoing allo-HSCT. Therefore, we aimed to develop a population pharmacokinetic (PopPK) model of vancomycin in patients undergoing allo-HSCT for effective and safe antimicrobial therapy and to develop a vancomycin dosing nomogram for a vancomycin optimal-dosing strategy. In total, 285 observations from 95 patients undergoing allo-HSCT were available. The final PopPK parameter estimates were central volume of distribution (V1, L), 39.2; clearance (L/h), 4.25; peripheral volume of distribution (V2, L), 56.1; and intercompartmental clearance (L/h), 1.95. The developed vancomycin model revealed an increase in V1 and V2 compared with those in the general population that consisted of patients with methicillin-resistant Staphylococcus aureus. Moreover, serum creatinine was reduced because of an increase in the plasma fraction because of destruction of hematopoietic stem cells accompanying allo-HSCT pretreatment, suggesting that the Cockcroft–Gault equation–based creatinine clearance value was overestimated. To our knowledge, this is the first PopPK study to develop a dosing nomogram for vancomycin in patients undergoing allo-HSCT and was proven to be useful in optimizing the dosage and dosing interval of vancomycin in these patients. This strategy will provide more useful information for vancomycin therapy with an evidence-based dose adjustment.

KW - allogeneic hematopoietic stem-cell transplantation

KW - population pharmacokinetics

KW - renal function

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=85047465294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047465294&partnerID=8YFLogxK

U2 - 10.1002/jcph.1106

DO - 10.1002/jcph.1106

M3 - Article

C2 - 29762865

AN - SCOPUS:85047465294

VL - 58

SP - 1140

EP - 1149

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 9

ER -